Infectious complications after kidney transplantation: current epidemiology and associated risk factors, Clin Transplant. août, vol.20, issue.4, pp.401-410, 2006. ,
Viral infection following kidney transplantation: long-term follow-up in a single center, Transplant Proc. sept, vol.36, issue.7, pp.2118-2127, 2004. ,
Human cytomegalovirus and kidney transplantation: a clinician's update, Am J Kidney Dis Off J Natl Kidney Found. juill, vol.58, issue.1, pp.118-144, 2011. ,
Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences, Clin Infect Dis Off Publ Infect Dis Soc Am. 1 mars, vol.46, issue.5, pp.732-772, 2008. ,
Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials, Lancet Lond Engl. 18 juin, vol.365, issue.9477, pp.2105-2120, 2005. ,
Optimization of outcomes related to cytomegalovirus in organ transplant recipients, Transplantation. 15 juill, vol.82, issue.1, pp.15-21, 2006. ,
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 mars, vol.46, issue.6, pp.840-846, 2008. ,
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.10, issue.5, pp.1228-1265, 2010. ,
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation, Transplantation, vol.102, issue.6, pp.900-931, 2018. ,
Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?, Transpl Int Off J Eur Soc Organ Transplant. déc, vol.28, issue.12, pp.1351-1357, 2015. ,
A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant, Clin Infect Dis Off Publ Infect Dis Soc Am. mars, vol.58, issue.6, pp.785-803, 2014. ,
Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year PostTransplantation: Can it Be Changed by Modifying Immunosuppression?, EBioMedicine, vol.34, pp.2-3, 2018. ,
CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study, EBioMedicine. août, vol.34, pp.113-134, 2018. ,
State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician, Clin Infect Dis Off Publ Infect Dis Soc Am. déc, vol.55, issue.12, pp.1678-89, 2012. ,
Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase, J Virol, vol.78, issue.20, pp.11030-11039, 2004. ,
Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant, Exp Clin Transplant Off J Middle East Soc Organ Transplant. août, vol.14, issue.4, pp.361-367, 2016. ,
Everolimustreated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporineor mycophenolate-treated patients, Transplantation. 15 janv, vol.95, issue.1, pp.184-91, 2013. ,
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation, J Am Soc Nephrol JASN. juill, vol.29, issue.7, pp.1979-91, 2018. ,
Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.11, issue.11, pp.2453-62, 2011. ,
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.15, issue.10, pp.2655-64, 2015. ,
CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and MetaAnalysis of Randomized, Controlled Trials, Clin J Am Soc Nephrol CJASN. 7 août, vol.12, issue.8, pp.1321-1357, 2017. ,
AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mars, vol.13, pp.179-88, 2013. ,
Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. juin, vol.10, issue.6, pp.1401-1414, 2010. ,
Place of mTOR inhibitors in management of BKV infection after kidney transplantation, J Nephropathol. janv, vol.5, issue.1, pp.1-7, 2016. ,
The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis, Transpl Infect Dis Off J Transplant Soc. août, vol.20, issue.4, p.12919, 2018. ,
The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial, Transpl Int Off J Eur Soc Organ Transplant, vol.31, issue.12, pp.1345-56, 2018. ,
The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients, Transpl Infect Dis Off J Transplant Soc. août, vol.20, issue.4, p.12907, 2018. ,
Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus, Transpl Infect Dis Off J Transplant Soc. avr, vol.20, issue.2, p.12846, 2018. ,
Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.17, issue.5, pp.1358-69, 2017. ,
Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. sept, vol.17, issue.9, pp.2363-71, 2017. ,
, mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis, vol.102, pp.44-50, 2018.
Infectious complications after kidney transplantation: current epidemiology and associated risk factors, Clin Transplant. août, vol.20, issue.4, pp.401-410, 2006. ,
Viral infection following kidney transplantation: long-term follow-up in a single center, Transplant Proc. sept, vol.36, issue.7, pp.2118-2127, 2004. ,
Human cytomegalovirus and kidney transplantation: a clinician's update, Am J Kidney Dis Off J Natl Kidney Found. juill, vol.58, issue.1, pp.118-144, 2011. ,
Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences ,
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group, N Engl J Med. 13 mai, vol.340, pp.1462-70, 1999. ,
Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. juin, vol.4, issue.6, pp.928-964, 2004. ,
The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection, J Clin Virol Off Publ Pan Am Soc Clin Virol. juin, vol.36, issue.2, pp.146-51, 2006. ,
Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients, Transplantation. 27 déc, vol.68, issue.12, pp.1879-83, 1999. ,
Current characteristics and outcome of cytomegalovirus infections after kidney transplantation, Transpl Infect Dis Off J Transplant Soc. août, vol.16, issue.4, pp.568-77, 2014. ,
Infection in Organ Transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.17, issue.4, pp.856-79, 2017. ,
Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation, Diabetologia. sept, vol.47, issue.9, pp.1550-1556, 2004. ,
Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients, J Infect Dis. 15 mai, vol.207, issue.10, pp.1569-75, 2013. ,
Kaposi's sarcoma in renal transplantation: report of three cases, Clin Nephrol. févr, vol.71, issue.2, pp.214-220, 2009. ,
AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. déc, vol.9, issue.4, pp.78-86, 2009. ,
, Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. nov, vol.9, issue.3, pp.1-155, 2009.
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group, Transplantation. 15 août, vol.60, issue.3, pp.225-257, 1995. ,
Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?, Transplant Proc. mars, vol.37, issue.2, pp.850-851, 2005. ,
Cytomegalovirus risk factors in renal transplantation with modern immunosuppression, Transpl Infect Dis Off J Transplant Soc. déc, vol.12, issue.6, pp.480-488, 2010. ,
Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials, Lancet Lond Engl. 18 juin, vol.365, issue.9477, pp.2105-2120, 2005. ,
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.10, issue.5, pp.1228-1265, 2010. ,
Optimization of outcomes related to cytomegalovirus in organ transplant recipients ,
,
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 mars, vol.46, issue.6, pp.840-846, 2008. ,
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants, Lancet Lond Engl. 19 août, vol.356, issue.9230, pp.645-654, 2000. ,
Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R-transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.5, issue.5, pp.1065-70, 2005. ,
Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease, Transplant Proc. août, vol.48, issue.6, pp.2056-2064, 2016. ,
Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation, Open Urol Nephrol J, vol.7, pp.152-159, 2014. ,
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation, Transplantation, vol.102, issue.6, pp.900-931, 2018. ,
State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician, Clin Infect Dis Off Publ Infect Dis Soc Am. déc, vol.55, issue.12, pp.1678-89, 2012. ,
Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?, Transpl Int Off J Eur Soc Organ Transplant. déc, vol.28, issue.12, pp.1351-1357, 2015. ,
DOI : 10.1111/tri.12629
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/tri.12629
A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant, Clin Infect Dis Off Publ Infect Dis Soc Am. mars, vol.58, issue.6, pp.785-803, 2014. ,
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial, Transplantation, vol.102, issue.5, pp.876-82, 2018. ,
Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. sept, vol.6, issue.9, pp.2134-2177, 2006. ,
Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey, Transpl Infect Dis Off J Transplant Soc. déc, vol.19, issue.6, 2017. ,
Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients, Transplantation, vol.92, issue.9, pp.1063-1071, 2011. ,
Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients, Transplantation. 27 janv, vol.91, issue.2, pp.251-256, 2011. ,
Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance, Transplantation. 15 févr, vol.89, issue.3, pp.320-326, 2010. ,
Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity, Clin Transplant. févr, vol.22, issue.1, pp.1-15, 2008. ,
DOI : 10.1111/j.1399-0012.2007.00739.x
Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med. 20 déc, vol.357, issue.25, pp.2562-75, 2007. ,
Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. oct, vol.5, issue.10, pp.2521-2551, 2005. ,
Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study, Transplantation. 27 juill, vol.80, issue.2, pp.244-52, 2005. ,
Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study, Transplantation, vol.78, issue.9, pp.1332-1372, 2004. ,
DOI : 10.1097/01.tp.0000140486.97461.49
Everolimus-based, calcineurininhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial, Lancet Lond Engl. 5 mars, vol.377, issue.9768, pp.837-884, 2011. ,
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. janv, vol.15, issue.1, pp.119-147, 2015. ,
Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. sept, vol.17, issue.9, pp.2363-71, 2017. ,
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation, J Am Soc Nephrol JASN. juill, vol.29, issue.7, pp.1979-91, 2018. ,
Randomized trial of everolimusfacilitated calcineurin inhibitor minimization over 24 months in renal transplantation, Transplantation. 15 avr, vol.95, issue.7, pp.933-975, 2013. ,
Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.17, issue.5, pp.1358-69, 2017. ,
Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation, Transpl Int Off J Eur Soc Organ Transplant. mai, vol.25, issue.5, pp.592-602, 2012. ,
Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel, Exp Clin Transplant Off J Middle East Soc Organ Transplant. juin, vol.15, issue.3, pp.241-52, 2017. ,
mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?, Transpl Int Off J Eur Soc Organ Transplant. juill, vol.30, issue.7, pp.647-57, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01911522
De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens, Exp Clin Transplant Off J Middle East Soc Organ Transplant, vol.16, issue.1, pp.23-30, 2018. ,
Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.10, issue.10, pp.2270-2278, 2010. ,
Sirolimus interacts with pathways essential for podocyte integrity, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc. févr, vol.24, issue.2, pp.630-638, 2009. ,
Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway, Transpl Immunol. juill, vol.23, issue.3, pp.125-157, 2010. ,
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.15, issue.10, pp.2655-64, 2015. ,
The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. févr, vol.13, issue.2, pp.442-451, 2013. ,
Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature, Transplantation. 27 sept, vol.94, issue.6, pp.547-61, 2012. ,
Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis, Kidney Int. avr, vol.71, issue.8, pp.771-778, 2007. ,
Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study, Transplantation. 19 févr, 2019. ,
Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. juin, vol.10, issue.6, pp.1401-1414, 2010. ,
CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials, Clin J Am Soc Nephrol CJASN. 7 août, vol.12, issue.8, pp.1321-1357, 2017. ,
Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors, Clin Dev Immunol, p.403280, 2013. ,
DOI : 10.1155/2013/403280
URL : https://doi.org/10.1155/2013/403280
, mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis, vol.102, pp.44-50, 2018.
Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients, Transplantation. 15 juin, vol.93, issue.11, pp.1075-85, 2012. ,
Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase, J Virol, vol.78, issue.20, pp.11030-11039, 2004. ,
Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant, Exp Clin Transplant Off J Middle East Soc Organ Transplant. août, vol.14, issue.4, pp.361-367, 2016. ,
Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication, J Virol. mai, vol.84, issue.10, pp.5260-5269, 2010. ,
DOI : 10.1128/jvi.02733-09
URL : http://europepmc.org/articles/pmc2863801?pdf=render
mTOR regulates memory CD8 Tcell differentiation, Nature. 2 juill, vol.460, issue.7251, pp.108-120, 2009. ,
DOI : 10.1038/nature08155
URL : http://europepmc.org/articles/pmc2710807?pdf=render
Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine-or mycophenolate-treated patients, Transplantation. 15 janv, vol.95, issue.1, pp.184-91, 2013. ,
Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.11, issue.11, pp.2453-62, 2011. ,
The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial, Transpl Int Off J Eur Soc Organ Transplant, vol.31, issue.12, pp.1345-56, 2018. ,
The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients, Transpl Infect Dis Off J Transplant Soc. août, vol.20, issue.4, p.12907, 2018. ,
Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus, Transpl Infect Dis Off J Transplant Soc. avr, vol.20, issue.2, p.12846, 2018. ,
Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients, Transpl Infect Dis Off J Transplant Soc. déc, vol.18, issue.6, pp.819-850, 2016. ,
The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients wit, PubMed -NCBI ,
Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid, Transpl Infect Dis Off J Transplant Soc. févr, vol.18, issue.1, pp.79-88, 2016. ,
AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mars, vol.13, pp.179-88, 2013. ,
Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors, J Infect Dis. 15 mars, vol.199, issue.6, pp.837-883, 2009. ,
Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues, J Infect Dis. avr, vol.147, issue.4, pp.676-84, 1983. ,
Polyoma virus nephropathy in kidney transplantation, World J Transplant. 24 déc, vol.7, issue.6, pp.329-367, 2017. ,
Identifying specific causes of kidney allograft loss, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mars, vol.9, issue.3, pp.527-562, 2009. ,
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. févr, vol.12, issue.2, pp.388-99, 2012. ,
BK virus infection: an update on diagnosis and treatment, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc. févr, vol.30, issue.2, pp.209-226, 2015. ,
Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review, J Clin Virol Off Publ Pan Am Soc Clin Virol. déc, vol.109, pp.6-12, 2018. ,
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary, Kidney Int. févr, vol.77, issue.4, pp.299-311, 2010. ,
Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection, Transplantation. 27 déc, vol.90, issue.12, pp.1450-1457, 2010. ,
Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation, vol.88, pp.1161-1169, 2009. ,
An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States, Transplantation. 15 avr, vol.87, issue.7, pp.1019-1045, 2009. ,
Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy, Transpl Infect Dis Off J Transplant Soc. déc, vol.18, issue.6, pp.850-855, 2016. ,
BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression, Transplantation, vol.78, issue.7, pp.1069-73, 2004. ,
Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients, Transpl Infect Dis Off J Transplant Soc. déc, vol.13, issue.6, pp.584-91, 2011. ,
BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition, BMC Nephrol, vol.14, p.207, 2013. ,
Everolimusbased immunosuppression therapy for BK virus nephropathy, Transplant Proc. févr, vol.47, issue.1, pp.57-61, 2015. ,
, Using mTOR Inhibitors in the Prevention of BK Nephropathy -Full Text View -ClinicalTrials
, Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients -Full Text View -ClinicalTrials.gov
,